{"abstract": "The Biotech giant Amgen said Wednesday it would buy Alantos Pharmaceuticals for $300 million, marking its second acquisition of a private biotech company this week. Alantos\u2019 lead drug is a small-molecule treatment for Type 2 diabetes.", "web_url": "https://dealbook.nytimes.com/2007/06/07/amgen-doubles-down-on-future-products/", "snippet": "", "lead_paragraph": "The Biotech giant Amgen said Wednesday it would buy Alantos Pharmaceuticals for $300 million, marking its second acquisition of a private biotech company this week. Alantos\u2019 lead drug is a small-molecule treatment for Type 2 diabetes.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Amgen Doubles Down on Future Products", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [], "pub_date": "2007-06-07T11:55:40+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Dealbook", "person": [{"firstname": "Dealbook", "middlename": null, "lastname": "", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/1094bf89-b980-576a-b710-f88109cfc38e", "word_count": 99, "uri": "nyt://article/1094bf89-b980-576a-b710-f88109cfc38e"}